PresentationAll right. Good morning, everyone. Welcome to Guggenheim Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here at Guggenheim. It is my pleasure to welcome Roivant Sciences here with me. From the company, we have the Chief Financial Officer, Richard Pulik. Richard, why don't you make some opening comments. You did the earnings call yesterday. There were some incremental updates. Why don't you just make some comments, and then we'll go into the Q&A.Richard Pul ...